{"filing":{"accession_number":"0001193125-26-326097","cik":"0001370053","ticker":"ANAB","company_name":"ANAPTYSBIO, INC","form":"8-K","filing_date":"2026-07-30","report_date":"2026-07-28","primary_document":"anab-20260728.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1370053/000119312526326097/anab-20260728.htm"},"events":[{"id":22603,"run_id":20449,"accession_number":"0001193125-26-326097","anchor_item_number":"7.01","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.92,"summary":"AnaptysBio disclosed material litigation against Tesaro and GlaxoSmithKline regarding alleged material breach of a Collaboration and Exclusive License Agreement and tortious interference. The filing provides substantive updates on trial completion (July 14-17, 2026) and a court-approved post-trial briefing schedule, indicating this is an ongoing material dispute with significant financial and operational implications for the Company's collaboration arrangements.","company_name":"ANAPTYSBIO, INC","ticker":"ANAB","filing_date":"2026-07-30","form":"8-K","submitted_at":null,"items":[{"id":22590,"accession_number":"0001193125-26-326097","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.92,"reasoning":"AnaptysBio disclosed material litigation against Tesaro and GlaxoSmithKline regarding alleged material breach of a Collaboration and Exclusive License Agreement and tortious interference. The filing provides substantive updates on trial completion (July 14-17, 2026) and a court-approved post-trial briefing schedule, indicating this is an ongoing material dispute with significant financial and operational implications for the Company's collaboration arrangements.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-01T02:22:38.492335+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":22590,"accession_number":"0001193125-26-326097","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.92,"reasoning":"AnaptysBio disclosed material litigation against Tesaro and GlaxoSmithKline regarding alleged material breach of a Collaboration and Exclusive License Agreement and tortious interference. The filing provides substantive updates on trial completion (July 14-17, 2026) and a court-approved post-trial briefing schedule, indicating this is an ongoing material dispute with significant financial and operational implications for the Company's collaboration arrangements.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-01T02:22:38.492335+00:00","company_name":"ANAPTYSBIO, INC","ticker":"ANAB","filing_date":"2026-07-30"}]}